Group 1 - The core point of the article is that the company,药石科技, plans to change the use of funds raised from a previous stock issuance to invest in two new projects instead of the originally planned project [1] - The original project was the "Annual Production of 155 Tons of Innovative Drugs and Key Intermediates CDMO Construction Project" at 浙江晖石药业有限公司 [1] - The new projects include the "Tides (Peptide/Oligonucleotide) New Molecular Drug R&D Service Platform Project" at 南京药石科技股份有限公司 and the "Chemical Synthesis New Molecular Drug Construction Project" at 浙江晖石药业有限公司 [1]

Core Viewpoint - Chengdu Shengnuo Biotechnology Co., Ltd. expects a significant increase in net profit for the fiscal year 2025, projecting a profit of approximately 152 million to 190 million yuan, representing a year-on-year growth of 204.42% to 280.53% [1] Group 1: Financial Performance - The company anticipates a net profit attributable to the parent company of around 152 million to 190 million yuan for 2025 [1] - This projected profit reflects a substantial increase compared to the previous year, indicating strong financial growth [1] Group 2: Business Strategy - The increase in profit is primarily attributed to the company's focus on its annual operational strategy, which includes the successful implementation of ongoing capacity expansion [1] - The company has been actively exploring both domestic and international markets, leading to a sustained growth in demand for its peptide raw material business [1] Group 3: Market Position - The overall performance improvement enhances the company's global competitiveness in the peptide pharmaceutical market [1]

证券日报网讯 1月15日，健康元在互动平台回答投资者提问时表示，公司始终密切关注汇率走势，积极 运用外汇衍生品等工具，并结合优化结算货币、合理规划外币收支等方式，对冲汇率波动风险，降低汇 兑损益。 （编辑 丛可心） ...

Core Viewpoint - XinNuoWei (300765) expects a net profit loss of 170 million to 255 million yuan for 2025, compared to a net profit of 53.7263 million yuan in the same period last year [1] Group 1: Financial Performance - The company anticipates a significant decline in net profit for 2025, projecting a loss between 170 million and 255 million yuan [1] - In the previous year, the company reported a net profit of 53.7263 million yuan [1] Group 2: Research and Development Investment - To accelerate the advancement of its innovative pipeline, the company has increased its R&D expenditure to approximately 1 billion yuan for the year, marking a substantial year-on-year increase [1] - The rise in R&D expenses is identified as a key factor impacting the current profit situation [1]

每经AI快讯，1月15日，圣诺生物(688117.SH)发布2025年度业绩预告，预计归属于母公司所有者的净利 润为1.52亿元至1.90亿元，与上年同期相比增加204.42%至280.53%。报告期内，公司推进在建产能落 地，持续开拓国内外市场，多肽原料药业务订单需求增长，带动整体业绩大幅提升。 ...

21智讯1月15日电，圣诺生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 15,228.31万元至19,035.38万元，同比预增204.42%—280.53%；预计2025年全年归属于上市公司股东的 扣除非经常性损益的净利润为14,872.70万元至18,590.88万元，同比预增226.07%—307.58%，报告期 内，公司紧密围绕年度经营战略，推进在建产能落地的同时，持续开拓国内外市场，使得公司多肽原料 药业务订单需求持续增长，带动公司整体业绩稳步提升，较上年同期业绩实现大幅增长，进一步增强公 司在多肽医药市场的全球化竞争力。 ...

格隆汇1月15日丨京新药业(002020.SZ)在互动平台表示，深圳巨烽主要提供医用显示模块解决方案，公 司会应用最新技术协助研发工作，但是在类人脑方面暂未有布局。 ...

Group 1 - The stock of Shanhe Pharmaceutical Auxiliary reached the daily limit, with a turnover rate of 20.85% and a transaction amount of 670 million yuan, showing a volatility of 14.94% [2] - The stock was listed on the Shenzhen Stock Exchange due to a closing price increase of 20.00%, with institutional proprietary seats net selling 360,600 yuan [2] - The top five trading departments accounted for a total transaction amount of 235 million yuan, with a net buying amount of 81.21 million yuan [2] Group 2 - The main capital inflow for the stock was 152 million yuan, with a large single net inflow of 217 million yuan and a net outflow of 65.39 million yuan from large orders [2] - Over the past five days, the net inflow of main capital was 159 million yuan [2] - Specific trading data shows that the top buying department was Kaiyuan Securities with a purchase amount of 61.01 million yuan, while the top selling department was Debon Securities with a selling amount of 32.36 million yuan [3]

融资融券数据显示，该股最新（1月14日）两融余额为3.91亿元，其中，融资余额为3.90亿元，融券余额 为45.37万元。近5日融资余额合计增加1.86亿元，增幅为91.49%，融券余额合计增加35.70万元，增幅 369.13%。（数据宝） 泓博医药1月15日交易公开信息 | | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 机构专用 | 1430.04 | 0.00 | | 买二 | 广发证券股份有限公司福州儒江西路证券营业部 | 1295.88 | 28.97 | | 买三 | 中国中金财富证券有限公司遂宁德水中路证券营业部 | 1124.80 | 1.58 | | 买四 | 华泰证券股份有限公司江西分公司 | 972.76 | 71.03 | | 买五 | 国泰海通证券股份有限公司重庆解放碑证券营业部 | 950.01 | 0.55 | | 卖一 | 机构专用 | 557.19 | 2618.59 | | 卖二 | 中信证券股份有限公司深圳滨海大道证券营业部 | 1.67 | 1721.75 | | 卖三 | 国金证券 ...

（记者 张明双） 京新药业（002020.SZ）1月15日在投资者互动平台表示，公司JX2201美国暂未开展临床试验，具体进 展敬请关注相关公告。 每经AI快讯，有投资者在投资者互动平台提问：公司JX2201国内已进入I期临床，美国IND获批，是不 是意味着可以在美国开展临床试验了？是不是公司海外授权的目标公司是美国药企？ ...